公开(公告)号：US20240343721A1

公开(公告)日：2024-10-17

申请号：US18635839

申请日：2024-04-15

申请人： Takeda Pharmaceutical Company Limited

发明人： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20210094944A1

公开(公告)日：2021-04-01

申请号：US17030504

申请日：2020-09-24

申请人： Takeda Pharmaceutical Company Limited

发明人： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC分类号： C07D413/14 ,  C07D413/10 ,  A61P25/28

摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20230183227A1

公开(公告)日：2023-06-15

申请号：US17952546

申请日：2022-09-26

申请人： Takeda Pharmaceutical Company Limited

发明人： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC分类号： C07D413/14 ,  A61P25/28 ,  C07D413/10

摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I)




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20220274982A1

公开(公告)日：2022-09-01

申请号：US17630840

申请日：2020-07-28

申请人： Takeda Pharmaceutical Company Limited

发明人： Yuta TANAKA ,  Yuta TANAKA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Yasufumi WADA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Tomohiro OHASHI ,  Junsi WANG ,  Zenichi IKEDA ,  Florian PUENNER ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC分类号： C07D471/04

摘要： The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.